LAMPRENE Drug Patent Profile
✉ Email this page to a colleague
When do Lamprene patents expire, and what generic alternatives are available?
Lamprene is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in LAMPRENE is clofazimine. There are five drug master file entries for this compound. Additional details are available on the clofazimine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LAMPRENE?
- What are the global sales for LAMPRENE?
- What is Average Wholesale Price for LAMPRENE?
Summary for LAMPRENE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 12 |
| DailyMed Link: | LAMPRENE at DailyMed |
Recent Clinical Trials for LAMPRENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Radboud University Medical Center | Phase 2 |
| Otsuka Pharmaceutical Co., Ltd. | Phase 2 |
| Harvard Medical School (HMS and HSDM) | Phase 2 |
US Patents and Regulatory Information for LAMPRENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LAMPRENE | clofazimine | CAPSULE;ORAL | 019500-002 | Dec 15, 1986 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | LAMPRENE | clofazimine | CAPSULE;ORAL | 019500-001 | Dec 15, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
